WO1986000811A1 - Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same - Google Patents
Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same Download PDFInfo
- Publication number
- WO1986000811A1 WO1986000811A1 PCT/HU1985/000048 HU8500048W WO8600811A1 WO 1986000811 A1 WO1986000811 A1 WO 1986000811A1 HU 8500048 W HU8500048 W HU 8500048W WO 8600811 A1 WO8600811 A1 WO 8600811A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- diseases
- preparations
- treatment
- avian
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 201000010099 disease Diseases 0.000 title claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 14
- 230000003612 virological effect Effects 0.000 title claims abstract description 9
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 6
- 241000700605 Viruses Species 0.000 claims abstract description 24
- 241000271566 Aves Species 0.000 claims abstract description 12
- 230000002238 attenuated effect Effects 0.000 claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 7
- 206010006451 bronchitis Diseases 0.000 claims abstract description 6
- 206010014599 encephalitis Diseases 0.000 claims abstract description 6
- 241000711404 Avian avulavirus 1 Species 0.000 claims abstract description 5
- 208000027932 Collagen disease Diseases 0.000 claims abstract description 5
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims abstract description 5
- 230000003211 malignant effect Effects 0.000 claims abstract description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 6
- 241000282412 Homo Species 0.000 abstract description 5
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000006758 Marek Disease Diseases 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000004196 common wart Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/255—Marek's disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to a set of therapeutic preparations (further on Preparation (s ) ) for the treatment of certain viral and other diseases , together with the complete technics of their production , including all materials and methods used.
- the Preparations are effective against various pathological conditions caused by the Herpes group of viruses , and against certain malignant and benign tumours and collagen diseases as well.
- Attenuated viral vaccines pre pared against some viral diseases of animals (Newcastle disease , Marek 's disease , avian bronchitis , avian encephalitis ) had a distinct therapeutic effect against various human diseases of known viral or unknown etiology.
- the ob ject of the present invention is a set of preparations containing attenuated (or killed)
- Newcastle disease virus Marek's disease virus , avian bronchitis virus or avian encephalitis virus , mixed in a carrier which is acceptable for use in humans.
- the present invention relates also to all materials and methods used in the production of all preparations. The Preparations have already been used with very good result in the conditions listed below:
- the Preparation containing attenuated Newcastle disease virus was active against the followin g conditions : a) Infections caused by viruses of the Herpes group , such as Herpex simplex I and II , Herpes zooster, Cytomegalovirus , infectious monon ⁇ cleoses (EpsteinBarr virus ) b) Aphthostomatitis c) Verruca vulgaris d) Infantile pharyngeal papilloma e) Human aden oca rein omas f ) Collagen diseases (e. g. nodous polyarteritis) g) Rheumatic arthritis
- the Prepa ration containing attenuated avian bronchitis virus was active against the following conditions : a) Various human cancers b) Infections caused by the above listed (1.a) viruses of the Herpes goup.
- the Preparations are produced by suspending live attenuated or inactivated , purified or highly purified and concentrated viruses in one of the carrier substances generally used in human pharmacology.
- the Preparations may be supplemented with potentiating drugs (e.g. tranquilizers).
- the optimal form of delivery of the Preparations is in a freeze-dried form , in sealed ampoules , with the diluent supplied in a separate vial.
- the Preparations can be stored at room temperature for a practically unlimited time, toother forms of delivery are in solution , suppository , capsule , emulsion , suspension , ointment , etc. These should be stored in cold , for their activity may decay repidly at room temperature.
- the dosage of the Preparations depends of their actual composition and form , on the patient 's general condition , and on stage (severity) of the disease actually treated.
- the Preparations are non-toxic , and have no side effect whatever.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Therapeutic preparations against certain viral and other diseases of humans. The preparations are specified as formulas containing attenuated Newcastle disease virus, Marek's disease virus, avian bronchitis virus or avian encephalitis virus, mixed in carrier substance generally used in human pharmacology, if desired along with one or more optional potentiating preparations. Another object of the invention is the use of the above viruses in the treatment of virus diseases as well as malignant and benign tumours and collagen diseases.
Description
THE REPAUTIC PREPARATIONS FOR TREATMENT OF CERTAIN VIRAL AND OTTER DISEASES AND THE PREPARATION OF THE SAME
Technical field
The present invention relates to a set of therapeutic preparations (further on Preparation (s ) ) for the treatment of certain viral and other diseases , together with the complete technics of their production , including all materials and methods used. The Preparations are effective against various pathological conditions caused by the Herpes group of viruses , and against certain malignant and benign tumours and collagen diseases as well.
Background art
Inactivated or live attenuated viruses have long been used all over the world for the specific prevention of several viral diseases of humans and animals. We have found that certain attenuated viral vaccines , pre pared against some viral diseases of animals (Newcastle disease , Marek 's disease , avian bronchitis , avian encephalitis ) had a distinct therapeutic effect against various human diseases of known viral or unknown etiology.
Disclosure of invention
Accordingly the ob ject of the present invention is a set of preparations containing attenuated (or killed)
Newcastle disease virus , Marek's disease virus , avian bronchitis virus or avian encephalitis virus , mixed in a carrier which is acceptable for use in humans. The present invention relates also to all materials and methods used in the production of all preparations.
The Preparations have already been used with very good result in the conditions listed below:
1. The Preparation containing attenuated Newcastle disease virus was active against the followin g conditions : a) Infections caused by viruses of the Herpes group , such as Herpex simplex I and II , Herpes zooster, Cytomegalovirus , infectious mononυcleoses (EpsteinBarr virus ) b) Aphthostomatitis c) Verruca vulgaris d) Infantile pharyngeal papilloma e) Human aden oca rein omas f ) Collagen diseases (e. g. nodous polyarteritis) g) Rheumatic arthritis
2. The Preparation containing attenuated Marek's disease virus acted against the following conditions : a ) Various human cancers (mainly a den oca rein omas ) b) Infections caused by viruses of the Herpes group as listed above (1.a)
3. The Prepa ration containing attenuated avian bronchitis virus was active against the following conditions : a) Various human cancers b) Infections caused by the above listed (1.a) viruses of the Herpes goup.
4. The Preparation containing attenuated avian encephalitis virus was active against the following conditions : a) Various human cancers
While most vaccines used for specific disease prevention in humans contain killed (inactivated) virus , all Preparations contain live attenuated virus. The possible mechanism of action of the Preparations is thus either an interference with the
virulent viruses responsible for the actual disease , or a highly efficient aspecific stimulation of the natural protective mechanisms operative in the organism involved by disease.
The Preparations are produced by suspending live attenuated or inactivated , purified or highly purified and concentrated viruses in one of the carrier substances generally used in human pharmacology. The Preparations may be supplemented with potentiating drugs (e.g. tranquilizers).
The optimal form of delivery of the Preparations is in a freeze-dried form , in sealed ampoules , with the diluent supplied in a separate vial. In this form , the Preparations can be stored at room temperature for a practically unlimited time, toother forms of delivery are in solution , suppository , capsule , emulsion , suspension , ointment , etc. These should be stored in cold , for their activity may decay repidly at room temperature.
The dosage of the Preparations depends of their actual composition and form , on the patient 's general condition , and on stage (severity) of the disease actually treated. The Preparations are non-toxic , and have no side effect whatever.
The Preparations were tested in humans and animals , and showed a great therapeutic efficiency in both clinical and experimental trials.
Claims
1. Therapeutic preparation for the treatment of viral diseases and against malignant and benign tumours and collagen diseases characterized by containing live attenuated viruses selected from the group consisting of Newcastle disease virus , Marek's disease virus , avian bronchitis virus and avian encephalitis virus.
2. The preparation according to claim 1 characterized by containing at least one carrier.
3. Use of Newcastle disease virus , Marek's disease virus , avian bronchitis virus and avian encephalitis virus in the treatment of viral diseases , against malignant and benign tumours and collagen diseases.
4. The use of viruses according to claim 3 in the treatment of diseases caused by the Herpes group of viruses.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU2919/84 | 1984-07-30 | ||
| HU842919A HU197517B (en) | 1984-07-30 | 1984-07-30 | Process for production of terapeutical composition applicable against virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1986000811A1 true WO1986000811A1 (en) | 1986-02-13 |
Family
ID=10961677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/HU1985/000048 WO1986000811A1 (en) | 1984-07-30 | 1985-07-29 | Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0188590A1 (en) |
| AU (1) | AU4638085A (en) |
| HU (1) | HU197517B (en) |
| WO (1) | WO1986000811A1 (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0260779A3 (en) * | 1986-09-15 | 1989-06-07 | Pitts, Ferris N., jr. | Use of an immunostimulating medicament |
| EP0331102A1 (en) * | 1988-03-01 | 1989-09-06 | Volker Prof. Dr. Schirrmacher | Virus-modified tumour vaccine for the immunotherapy of tumour metastases |
| EP0292293A3 (en) * | 1987-05-19 | 1990-01-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Newcastle disease virus vaccine and method for the applicaton thereof |
| EP0312839A3 (en) * | 1987-10-17 | 1990-03-14 | Bayer Ag | Method for the preparation of an inducer of non-specific immunity |
| US5602023A (en) * | 1992-03-24 | 1997-02-11 | Csatary; Laszlo K. | Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same |
| US7056689B1 (en) | 1993-04-30 | 2006-06-06 | Wellstat Biologics Corporation | Methods of treating and detecting cancer using viruses |
| US7470426B1 (en) | 1997-10-09 | 2008-12-30 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| US7780962B2 (en) | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
| US8043612B2 (en) | 1997-10-09 | 2011-10-25 | Wellstat Biologics Corporation | Infection and treatment of neoplasms with vesicular stomatitis virus |
| US8105578B2 (en) | 1997-10-09 | 2012-01-31 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| US8147822B1 (en) | 1999-09-17 | 2012-04-03 | Wellstat Biologics Corporation | Oncolytic virus |
| US8377450B2 (en) | 2009-11-30 | 2013-02-19 | United Cancer Research Institute | Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0713397B1 (en) * | 1992-03-24 | 2002-12-11 | United Cancer Research Institute | Vaccine containing live virus |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1492083A1 (en) * | 1962-02-01 | 1969-08-07 | Philips Roxane | Method for selecting a virus or other organism with the ability to induce protective resistance in an animal against a pathogen that is immunologically unrelated to the virus or organism |
| US3548054A (en) * | 1969-06-06 | 1970-12-15 | Lilly Co Eli | Method for improving weight gains and reducing gross lesions in chickens exposed to marek's disease |
| DE2120929A1 (en) * | 1970-04-29 | 1971-11-18 | Merck & Co. Inc., Rahway, N.J. (V.StA.) | Marek's chicken paralysis vaccine for poultry and process for its preparation |
| GB1274820A (en) * | 1969-11-29 | 1972-05-17 | Takeda Chemical Industries Ltd | Highly attenuated newcastle disease virus vaccine and production thereof |
| US3674861A (en) * | 1968-11-18 | 1972-07-04 | Anthony Edward Churchill | Live attenuated marek{40 s disease virus vaccine for poultry |
| US4049794A (en) * | 1974-06-24 | 1977-09-20 | Bayer Aktiengesellschaft | Treatment of infections in animals |
| AT343797B (en) * | 1974-08-01 | 1978-06-12 | Stickl Helmut | METHOD FOR PRODUCING A PREPARATION FOR TREATING INTERFERON-SENSITIVE INFECTIOUS DISEASES |
| AT346476B (en) * | 1973-07-19 | 1978-11-10 | Sevoian Martin | METHOD FOR PRODUCING A VACCINE FOR IMMUNIZING POULTRY AGAINST MAREK'S DISEASE |
| FR2444467A1 (en) * | 1978-12-20 | 1980-07-18 | Gist Brocades Nv | VACCINES FOR DISEASES CAUSED BY REOVIRUSES AND PROCESS FOR THE PREPARATION THEREOF |
| US4357320A (en) * | 1980-11-24 | 1982-11-02 | Gist-Brocades N. V. | Infectious bronchitis vaccine for poultry |
| JPS58116422A (en) * | 1981-12-28 | 1983-07-11 | Green Cross Corp:The | Antitumor agent |
| EP0086025A1 (en) * | 1982-02-05 | 1983-08-17 | Akzo N.V. | Infectious bronchitis vaccines |
-
1984
- 1984-07-30 HU HU842919A patent/HU197517B/en not_active IP Right Cessation
-
1985
- 1985-07-29 WO PCT/HU1985/000048 patent/WO1986000811A1/en unknown
- 1985-07-29 EP EP85903869A patent/EP0188590A1/en not_active Withdrawn
- 1985-07-29 AU AU46380/85A patent/AU4638085A/en not_active Abandoned
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1492083A1 (en) * | 1962-02-01 | 1969-08-07 | Philips Roxane | Method for selecting a virus or other organism with the ability to induce protective resistance in an animal against a pathogen that is immunologically unrelated to the virus or organism |
| US3674861A (en) * | 1968-11-18 | 1972-07-04 | Anthony Edward Churchill | Live attenuated marek{40 s disease virus vaccine for poultry |
| US3548054A (en) * | 1969-06-06 | 1970-12-15 | Lilly Co Eli | Method for improving weight gains and reducing gross lesions in chickens exposed to marek's disease |
| GB1274820A (en) * | 1969-11-29 | 1972-05-17 | Takeda Chemical Industries Ltd | Highly attenuated newcastle disease virus vaccine and production thereof |
| DE2120929A1 (en) * | 1970-04-29 | 1971-11-18 | Merck & Co. Inc., Rahway, N.J. (V.StA.) | Marek's chicken paralysis vaccine for poultry and process for its preparation |
| AT346476B (en) * | 1973-07-19 | 1978-11-10 | Sevoian Martin | METHOD FOR PRODUCING A VACCINE FOR IMMUNIZING POULTRY AGAINST MAREK'S DISEASE |
| US4049794A (en) * | 1974-06-24 | 1977-09-20 | Bayer Aktiengesellschaft | Treatment of infections in animals |
| AT343797B (en) * | 1974-08-01 | 1978-06-12 | Stickl Helmut | METHOD FOR PRODUCING A PREPARATION FOR TREATING INTERFERON-SENSITIVE INFECTIOUS DISEASES |
| FR2444467A1 (en) * | 1978-12-20 | 1980-07-18 | Gist Brocades Nv | VACCINES FOR DISEASES CAUSED BY REOVIRUSES AND PROCESS FOR THE PREPARATION THEREOF |
| US4357320A (en) * | 1980-11-24 | 1982-11-02 | Gist-Brocades N. V. | Infectious bronchitis vaccine for poultry |
| JPS58116422A (en) * | 1981-12-28 | 1983-07-11 | Green Cross Corp:The | Antitumor agent |
| EP0086025A1 (en) * | 1982-02-05 | 1983-08-17 | Akzo N.V. | Infectious bronchitis vaccines |
Non-Patent Citations (1)
| Title |
|---|
| Patent Abstracts of Japan, unexamined applications, section C, vol. 7, no. 219, issued 30 March 1983, The Patent Office Japanese Government, page 76 C 188, see Kokai-no. 58-116 422 (Midori Juji K.K.). * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0260779A3 (en) * | 1986-09-15 | 1989-06-07 | Pitts, Ferris N., jr. | Use of an immunostimulating medicament |
| EP0292293A3 (en) * | 1987-05-19 | 1990-01-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Newcastle disease virus vaccine and method for the applicaton thereof |
| US5152981A (en) * | 1987-05-19 | 1992-10-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Newcastle disease virus vaccine and method for the application thereof |
| EP0312839A3 (en) * | 1987-10-17 | 1990-03-14 | Bayer Ag | Method for the preparation of an inducer of non-specific immunity |
| US5094850A (en) * | 1987-10-17 | 1992-03-10 | Bayer Aktiengesellschaft | Process for the preparation of inducers of non-specific immunity and product produced |
| EP0331102A1 (en) * | 1988-03-01 | 1989-09-06 | Volker Prof. Dr. Schirrmacher | Virus-modified tumour vaccine for the immunotherapy of tumour metastases |
| WO1989007946A1 (en) * | 1988-03-01 | 1989-09-08 | Deutsches Krebsforschungszentrum | Virally modified tumour vaccines for immunotherapy of tumour metastases |
| US5602023A (en) * | 1992-03-24 | 1997-02-11 | Csatary; Laszlo K. | Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same |
| US7056689B1 (en) | 1993-04-30 | 2006-06-06 | Wellstat Biologics Corporation | Methods of treating and detecting cancer using viruses |
| US7736640B2 (en) | 1993-04-30 | 2010-06-15 | Wellstat Biologics Corporation | Methods of treating and detecting cancer using viruses |
| US7470426B1 (en) | 1997-10-09 | 2008-12-30 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| US7780962B2 (en) | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
| US8043612B2 (en) | 1997-10-09 | 2011-10-25 | Wellstat Biologics Corporation | Infection and treatment of neoplasms with vesicular stomatitis virus |
| US8105578B2 (en) | 1997-10-09 | 2012-01-31 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| US8147822B1 (en) | 1999-09-17 | 2012-04-03 | Wellstat Biologics Corporation | Oncolytic virus |
| US8377450B2 (en) | 2009-11-30 | 2013-02-19 | United Cancer Research Institute | Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0188590A1 (en) | 1986-07-30 |
| AU4638085A (en) | 1986-02-25 |
| HU197517B (en) | 1989-04-28 |
| HUT40572A (en) | 1987-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Potkay | Diseases of the Callitrichidae: a review | |
| Käufer et al. | Significance of bursa of Fabricius as target organ in infectious bursal disease of chickens | |
| Habel et al. | Relationship of polyoma virus and tumor in vivo | |
| Zawatzky et al. | The Role of Interferon in the Resistance of CS7BL/6 Mice to Various Doses of Herpes Simplex Virus Type 1 | |
| US4053582A (en) | Attenuated fowl pox virus preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use | |
| WO1986000811A1 (en) | Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same | |
| Seay et al. | Experimental viral polymyositis: age dependency and immune responses to Ross River virus infection in mice | |
| STRINGFELLOW et al. | Interferon induction by 5-halo-6-phenyl pyrimidinones | |
| Wagner | Cellular resistance to viral infection, with particular reference to endogenous interferon | |
| Borden et al. | The interferon refractory state: in vivo and in vitro studies of its mechanism | |
| CA1095407A (en) | Preparation for the treatment of herpes zoster and other herpes infections, as well as method for manufacture thereof | |
| WO1986000529A1 (en) | An antiviral preparation and the method of its production | |
| Klein et al. | Immune response and latent infection after topical treatment of herpes simplex virus infection in hairless mice | |
| Stringfellow et al. | Interferon inducers in therapy of infection with encephalomyocarditis virus in mice. I. Effect of single doses of polyriboinosinic-polyribocytidylic acid and tilorone hydrochloride on viral pathogenesis | |
| US4049794A (en) | Treatment of infections in animals | |
| RU2005475C1 (en) | Antiviral agent | |
| Melnick et al. | Photodynamic inactivation of herpesvirus | |
| EP0351908B1 (en) | Live newcastle disease virus vacccines | |
| Vizoso et al. | Isolation of a virus resembling encephalomyocarditis from a red squirrel | |
| US4017359A (en) | Production of non-antigenic attenuated viruses | |
| US6080726A (en) | Anti-viral and immuno stimulator polynucleotide duplex and use thereof | |
| JPH03500656A (en) | Acyl carnitine, a drug for the treatment and prevention of viral infections | |
| RU94016333A (en) | DRUG FOR THE TREATMENT OF VIRAL DISEASES | |
| Stringfellow et al. | Feline interferon response to 2-amino-5-bromo-6-methyl-4-pyrimidinol (U-25,166) | |
| RU2180238C1 (en) | Biological preparation to prevent and treat gastrointestinal and respiratory diseases in calves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Designated state(s): AU BR DK FI JP MC NO RO SU US |
|
| AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB IT LU NL SE |